Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A E Arndt

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Current Pharmaceutical Design|August 20, 2009
Ribonucleases and immunoRNases as anticancer drugsS M Rybak, M A E Arndt, T Schirrmann, et al.
British Journal of Cancer|May 20, 2004
Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzymeJ Krauss, M A E Arndt, Z Zhu, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Current Pharmaceutical Design|August 20, 2009
Ribonucleases and immunoRNases as anticancer drugsS M Rybak, M A E Arndt, T Schirrmann, et al.
British Journal of Cancer|May 20, 2004
Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzymeJ Krauss, M A E Arndt, Z Zhu, et al.
Pageof 1